DOCK2 and schizophrenia: Based on GSEA, correlation, and PPI analysis, we conclude that DOCK2 acts as a molecular hub for channelized signaling in microglia-based neuroprotection, neuroinflammation, and neurological diseases, including AD and PD, Autism spectrum disorders, and schizophrenia (63).